Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database

Upadacitinib, a Janus kinase (JAK) inhibitor, has been approved by the FDA to treat various autoimmune conditions. This study assessed its adverse events by analyzing reports from the FDA Adverse Event Reporting System (FAERS).